<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743482</url>
  </required_header>
  <id_info>
    <org_study_id>INT123/12</org_study_id>
    <nct_id>NCT01743482</nct_id>
  </id_info>
  <brief_title>Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors</brief_title>
  <acronym>Pazotest-01</acronym>
  <official_title>Phase II Study of Single-agent Pazopanib (VotrientÂ®) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single arm, single center, phase 2 study with the use of the
      antiangiogenic multikinase inhibitor pazopanib in a population of patients with germ cell
      tumors who are not cured following first or subsequent chemotherapy lines for metastatic
      disease, followed by eventual surgery.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>3-months</time_frame>
    <description>To evaluate the proportion of patients who are progression-free after 3 months of pazopanib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of pazopanib according to the Common Terminology Criteria for Adverse Events version 4.03</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>3 months</time_frame>
    <description>A response rate will be considered as the sum of complete (CR) and partial responses (PR) according to the response evaluation criteria in solid tumors (RECIST), version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6 months</time_frame>
    <description>OS time will be calculated as the interval from treatment start date to the date of death for any cause, with censoring at the date of last contact for patients alive. The Kaplan-Meier method will be used to estimate the OS curve.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Germ Cell Tumors</condition>
  <condition>Measurable Disease</condition>
  <condition>Relapse or Progression After 2 or 3 Chemotherapy Regimens.</condition>
  <condition>Relapse or Progression After High-dose Chemotherapy.</condition>
  <arm_group>
    <arm_group_label>Pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive pazopanib at the dose of 800 mg/day orally until disease progression or evidence of unacceptable toxicity/side effects. The study will be performed according to Simon's two-stage optimal design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <arm_group_label>Pazopanib</arm_group_label>
    <other_name>Votrient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male gender.

          -  Confirmation of GCT histology based on pathologic review at Fondazione INT Milan.

          -  Unequivocal progression of measurable disease.

          -  A minimum of 2 and a maximum of 3 platinum-based chemotherapy lines for metastatic
             disease.

          -  First-line therapy should consist of at least 3 cycles of cisplatin-based
             chemotherapy.

          -  Prior single, tandem or triple high-dose chemotherapy course given as front-line or
             salvage therapy is allowed.

        Exclusion Criteria:

          -  Failure to meet any of the above inclusion criteria.

          -  Concurrent treatment with other cytotoxic drugs or targeted therapies.

          -  Prior radiation therapy within 14 days of trial start.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Necchi, MD</last_name>
    <phone>+39-02-2390-2402</phone>
    <email>andrea.necchi@istitutotumori.mi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>Mi</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Necchi, MD</last_name>
      <phone>+39 02 2390 2402</phone>
      <email>andrea.necchi@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Patrizia Giannatempo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Necchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</investigator_affiliation>
    <investigator_full_name>Andrea Necchi</investigator_full_name>
    <investigator_title>Faculty, Department of Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>Testicular Cancer</keyword>
  <keyword>Germ Cell Tumors</keyword>
  <keyword>Salvage Therapy</keyword>
  <keyword>Pazopanib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

